Replies to post #110438 on Biotech Values

[Biowatch]

Contrave: FDA Advisory panel vote 13 to 7 that "the evidence indicates that the potential benefits of the drug Contrave outweigh its risks."

13 to 7 is NOT an overwhelming stamp of approval.

The FDA has to consider that a wide range of people with many health issues might take this for years. The FDA has to balance potential, perhaps unknown, risks against whether diet and exercise would have fewer side effects.